Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring.

Severe diabetic ketoacidosis (DKA) is a critical medical condition that often necessitates emergency treatment and hospitalization. Although DKA primarily impacts individuals with type 1 diabetes (T1D), its annual incidence among adults with T1D ranges from 4% to 8% following diagnosis. Continuous glucose monitoring (CGM) has become a standard tool for managing T1D and type 2 diabetes (T2D) in patients using insulin or aiming to improve self-management. However, advances in continuous dual glucose-ketone monitoring (DGK) technology offer new possibilities for clinical research and patient care. This article explores the potential applications of DGK in clinical research, with a focus on T1D, while also considering its broader relevance for T2D and other patient populations.